Skip to main content
. Author manuscript; available in PMC: 2017 Jul 26.
Published in final edited form as: Int J Cancer. 2016 Feb 3;138(11):2602–2615. doi: 10.1002/ijc.29994

Table 3.

Hazard ratios (HR) and 95% confidence intervals (CI) for breast cancer incidence in relation to WCRF/AICR adherence score

Reference WCRF/AICR Adherence Scores
Unadjusted HR
WCRF/AICR Adherence Scores
Multivariable Adjusted HR
N Cases/N
Total
Group 1
(0 − 3.5)
Group 2
(4.0 − 4.5)
Group 3
(5.0 − 5.5)
Group 4
(6.0 − 8.0)
Ptrend1 Pint Group 2
(4.0 − 4.5)
Group 3
(5.0 − 5.5)
Group 4
(6.0 − 8.0)
Ptrend1 Pint

Overall2 3,189/36,626 1.0 (ref) 1.01 (0.91–1.12) 1.04 (0.93–1.15) 0.90 (0.80–1.02) 0.07 --- 0.92 (0.83–1.03) 0.90 (0.81–1.00) 0.76 (0.67–0.87) <0.001 ---

Height2,3 0.78 0.50
  ≤160 cm 742/9,873 1.0 (ref) 1.06 (0.86–1.32) 1.10 (0.89–1.36) 0.86 (0.67–1.12) 0.20 0.98 (0.78–1.22) 0.98 (0.78–1.23) 0.73 (0.55–0.96) 0.08
  >160–<165 cm 1,400/16,113 1.0 (ref) 0.96 (0.83–1.13) 0.95 (0.81–1.11) 0.88 (0.74–1.06) 0.59 0.85 (0.72–1.00) 0.79 (0.67–0.93) 0.73 (0.60–0.89) 0.008
  ≥ 165 cm 1,047/10,640 1.0 (ref) 1.02 (0.85–1.23) 1.10 (0.91–1.32) 0.92 (0.75–1.14) 0.31 0.99 (0.81–1.20) 1.02 (0.83–1.24) 0.84 (0.67–1.05) 0.24

Fertility Years3,4,5 0.70 0.66
  ≤ 33 978/12,009 1.0 (ref) 1.03 (0.86–1.23) 1.04 (0.86–1.24) 0.85 (0.68–1.06) 0.22 0.93 (0.77–1.13) 0.93 (0.77–1.13) 0.72 (0.57–0.91) 0.03
  34–38 years 1,062/12,177 1.0 (ref) 1.02 (0.86–1.22) 0.96 (0.80–1.15) 0.95 (0.77–1.17) 0.82 0.90 (0.75–1.08) 0.78 (0.65–0.95) 0.74 (0.59–0.92) 0.02
  ≥ 39 years 1,040/10,969 1.0 (ref) 0.94 (0.78–1.13) 1.04 (0.87–1.25) 0.88 (0.71–1.09) 0.28 0.92 (0.76–1.12) 0.98 (0.81–1.19) 0.81 (0.65–1.01) 0.18

Parity6 0.12 0.09
  None 292/3,272 1.0 (ref) 1.18 (0.84–1.67) 0.95 (0.67–1.35) 0.73 (0.48–1.10) 0.05 1.08 (0.75–1.57) 0.78 (0.53–1.14) 0.66 (0.42–1.05) 0.04
  1–2 children 1,074/11,702 1.0 (ref) 0.91 (0.76–1.09) 1.05 (0.88–1.25) 0.80 (0.65–0.99) 0.02 0.81 (0.66–0.98) 0.89 (0.74–1.08) 0.68 (0.54–0.85) 0.004
  3 or more 1,277/14,437 1.0 (ref) 1.07 (0.91–1.27) 1.04 (0.88–1.23) 0.97 (0.80–1.18) 0.66 1.02 (0.86–1.22) 0.94 (0.79–1.12) 0.83 (0.68–1.02) 0.13

Family History7,8 0.69 0.60
  None 2,137/26,766 1.0 (ref) 0.97 (0.85–1.10) 0.99 (0.88–1.13) 0.86 (0.75–1.00) 0.16 0.86 (0.76–0.98) 0.84 (0.74–0.96) 0.70 (0.60–0.82) <0.001
  Second Degree 392/3,946 1.0 (ref) 1.30 (0.95–1.78) 1.31 (0.96–1.78) 1.14 (0.79–1.63) 0.30 1.20 (0.86–1.66) 1.18 (0.85–1.64) 1.01 (0.69–1.48) 0.54
  First Degree 523/4,232 1.0 (ref) 1.07 (0.83–1.38) 1.08 (0.83–1.39) 0.96 (0.71–1.29) 0.80 0.99 (0.76–1.29) 0.99 (0.75–1.30) 0.88 (0.64–1.21) 0.83

Combined Factors9 0.40 0.57
  None 968/11,861 1.0 (ref) 1.02 (0.85–1.23) 0.96 (0.80–1.16) 0.94 (0.75–1.17) 0.41 0.92 (0.76–1.11) 0.81 (0.67–0.99) 0.74 (0.59–0.93) 0.001
  1 risk factor 1,241/12,979 1.0 (ref) 0.88 (0.75–1.04) 1.00 (0.85–1.18) 0.78 (0.64–0.95) 0.12 0.82 (0.70–0.98) 0.89 (0.75–1.05) 0.69 (0.56–0.84) 0.003
  2 risk factors 627/5,059 1.0 (ref) 1.18 (0.92–1.51) 1.12 (0.88–1.44) 1.09 (0.82–1.44) 0.57 1.14 (0.89–1.47) 1.05 (0.81–1.35) 0.99 (0.74–1.31) 0.81
  3+ risk factors 101/651 1.0 (ref) 1.19 (0.63–2.27) 1.11 (0.59–2.08) 0.75 (0.35–1.58) 0.56 1.08 (0.57–2.08) 1.13 (0.60–2.16) 0.76 (0.36–1.63) 0.84
1

Score evaluated as a continuous variable Cox regression model.

2

Unadjusted and adjusted for age, smoking, education, hormone replacement therapy, family history of breast cancer, menarche age, menopause age, and parity.

3

Tertiles.

4

Age at menopause – age at menarche = years of potential fertility.

5

Unadjusted and adjusted for age, smoking, education, hormone replacement therapy, family history of breast cancer, and parity.

6

Unadjusted and adjusted for age, smoking, education, hormone replacement therapy, family history of breast cancer, menopause age, and menarche age.

7

Unadjusted and adjusted for age, smoking, education, hormone replacement therapy, menopause age, menarche age, and parity.

8

Breast cancer; second degree = grandmother only, First degree = history in mother/sister.

9

Unadjusted and adjusted for age, smoking, education and hormone replacement therapy.